US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
US6887471B1
(en)
*
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
US20050002902A1
(en)
*
|
1995-12-28 |
2005-01-06 |
Liming Yu |
Hybrid with interferon-alpha and an immunoglobulin Fc for treatment of tumors and viral infections
|
US6750334B1
(en)
*
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
PT892643E
(pt)
*
|
1996-03-20 |
2002-09-30 |
Univ Emory |
Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
AU9095498A
(en)
*
|
1997-09-19 |
1999-04-12 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Oligopeptide compounds
|
EP1037927B1
(de)
*
|
1997-12-08 |
2004-05-19 |
Lexigen Pharmaceuticals Corp. |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
CA2328076C
(en)
*
|
1998-04-15 |
2009-10-06 |
Lexigen Pharmaceuticals Corporation |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
|
IL126681A0
(en)
*
|
1998-10-21 |
1999-08-17 |
Opperbas Holding Bv |
Treatment of trauma-related conditions
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
DE60035871T2
(de)
*
|
1999-05-19 |
2008-06-05 |
Merck Patent Gmbh |
Expression und export von interferon-alpha proteinen als fc fusionsproteine
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
MXPA02001417A
(es)
*
|
1999-08-09 |
2002-08-12 |
Lexigen Pharm Corp |
Complejos multiples de citosina-anticuerpo.
|
JP4896327B2
(ja)
|
1999-08-23 |
2012-03-14 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
Pd−1、b7−4の受容体、およびその使用
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
ES2269366T3
(es)
*
|
2000-02-11 |
2007-04-01 |
Merck Patent Gmbh |
Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
|
US7416726B2
(en)
|
2000-04-13 |
2008-08-26 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
WO2001095928A2
(en)
*
|
2000-06-09 |
2001-12-20 |
Bristol-Myers Squibb Company |
Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
|
JP2004501624A
(ja)
|
2000-06-28 |
2004-01-22 |
ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー |
Pd−l2分子:新規pd−1リガンドおよびその使用
|
DE60129695T2
(de)
*
|
2000-06-29 |
2008-06-05 |
Merck Patent Gmbh |
Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
KR100864120B1
(ko)
*
|
2000-07-03 |
2008-10-16 |
브리스톨-마이어스스퀴브컴파니 |
가용성 ctla4 분자를 사용한 류마티스성 질환의 치료법
|
EP1179587A1
(de)
*
|
2000-08-09 |
2002-02-13 |
Genethor GmbH |
Verfahren zur Reduzierung von spezifischen Immunreaktionen
|
IL155812A0
(en)
*
|
2000-12-07 |
2003-12-23 |
Lilly Co Eli |
Glp-1 fusion proteins
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
HUP0303930A3
(en)
*
|
2001-01-26 |
2012-09-28 |
Univ Emory |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
CN1330664C
(zh)
*
|
2001-03-07 |
2007-08-08 |
默克专利有限公司 |
用于含杂合同种型抗体部分的蛋白质的表达技术
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
EP2388590A1
(de)
|
2001-04-02 |
2011-11-23 |
Dana Farber Cancer Institute |
PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
CN100503639C
(zh)
|
2001-05-03 |
2009-06-24 |
默克专利有限公司 |
重组肿瘤特异性抗体及其应用
|
DK1397153T3
(da)
|
2001-05-23 |
2008-05-26 |
Bristol Myers Squibb Co |
Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler
|
KR100453877B1
(ko)
*
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
MXPA04005266A
(es)
*
|
2001-12-04 |
2004-10-11 |
Merck Patent Gmbh |
Inmunocitocinas con selectividad modulada.
|
US20030144193A1
(en)
*
|
2001-12-20 |
2003-07-31 |
Rottman James B. |
TANGO 197 and TANGO 216 compositions and methods
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
AU2003222141A1
(en)
*
|
2002-03-29 |
2003-10-13 |
Repligen Corporation |
Ctla4 compositions in the treatment of autism
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
JP2006519762A
(ja)
*
|
2002-10-09 |
2006-08-31 |
ライナット ニューロサイエンス コーポレイション |
アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217798B2
(en)
|
2003-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of Fc-fusion protein serum half-lives by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7169904B2
(en)
|
2002-12-17 |
2007-01-30 |
Emd Lexigen Research Center Corp. |
Immunocytokine sequences and uses thereof
|
EP1575998A4
(de)
*
|
2002-12-23 |
2007-07-25 |
Bristol Myers Squibb Co |
Verfahren zur kultivierung vonsäugetierzellen zur proteinproduktion
|
MXPA05006522A
(es)
*
|
2002-12-23 |
2006-02-17 |
Bristol Myers Squibb Co |
Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
JP2007527696A
(ja)
|
2003-04-03 |
2007-10-04 |
ラボラトワール フランセ デュ フラクションヌメント エ デ バイオテクノロジーズ |
細胞機能を調節する能力が増強された治療産物
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
*
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
ES2298785T3
(es)
*
|
2003-06-12 |
2008-05-16 |
Eli Lilly And Company |
Proteinas de fusion.
|
CN1802386B
(zh)
|
2003-06-12 |
2010-12-15 |
伊莱利利公司 |
Glp-1类似物融合蛋白质
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
MXPA06001225A
(es)
*
|
2003-08-04 |
2006-04-11 |
Bristol Myers Squibb Co |
Metodos de tratamiento de enfermedad cardiovascular usando una molecula soluble de ctla4.
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
WO2005044188A2
(en)
*
|
2003-10-27 |
2005-05-19 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
CN103212084B
(zh)
*
|
2003-11-13 |
2018-07-13 |
韩美科学株式会社 |
含有免疫球蛋白fc区作为载体的药物组合物
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
US20050191276A1
(en)
*
|
2003-11-25 |
2005-09-01 |
Gregory Gurtner |
Treatment of inflammatory bowel disease through induction of indoleamine 2.3-dioxygenase
|
US20050238651A1
(en)
*
|
2003-11-25 |
2005-10-27 |
Gurtner Gregory J |
Treatment of inflammatory bowel disease
|
WO2005063820A2
(en)
*
|
2003-12-30 |
2005-07-14 |
Merck Patent Gmbh |
Il-7 fusion proteins
|
DK1699821T3
(da)
*
|
2003-12-31 |
2012-07-16 |
Merck Patent Gmbh |
Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
|
CA2552590A1
(en)
*
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
WO2005092925A2
(en)
*
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
WO2005110474A2
(en)
|
2004-05-10 |
2005-11-24 |
Macrogenics, Inc. |
HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
KR100542605B1
(ko)
*
|
2004-05-28 |
2006-01-11 |
보령제약 주식회사 |
에이치씨티엘에이4-아이지 융합단백질 유전자를 포함하는재조합 벡터 및 이를 이용한 에이치씨티엘에이4-아이지융합 단백질의 생산방법
|
US7670595B2
(en)
*
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
NZ541496A
(en)
*
|
2004-07-28 |
2007-06-29 |
Debra Leonard |
Catchment means to enable water precipitate collection from an upper surface of a water storage receptacle
|
CA2573192C
(en)
|
2004-08-04 |
2013-09-10 |
Applied Molecular Evolution Inc. |
Variant fc regions
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP2845865A1
(de)
|
2004-11-12 |
2015-03-11 |
Xencor Inc. |
FC-Varianten mit Veränderter Bindung zu FCRN
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US7589179B2
(en)
*
|
2004-12-09 |
2009-09-15 |
Merck Patent Gmbh |
IL-7 variants with reduced immunogenicity
|
JP2008531049A
(ja)
*
|
2005-02-28 |
2008-08-14 |
セントカー・インコーポレーテツド |
ヘテロ二量体タンパク質結合組成物
|
US20110123440A1
(en)
*
|
2005-03-29 |
2011-05-26 |
Genevieve Hansen |
Altered Antibody FC Regions and Uses Thereof
|
CN101198347A
(zh)
*
|
2005-04-06 |
2008-06-11 |
布里斯托尔-迈尔斯斯奎布公司 |
使用可溶性ctla4突变型分子治疗与移植物移植有关的免疫病症的方法
|
EP1868650B1
(de)
|
2005-04-15 |
2018-10-03 |
MacroGenics, Inc. |
Kovalente diabodies und ihre verwendung
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
PT2298815E
(pt)
|
2005-07-25 |
2015-07-16 |
Emergent Product Dev Seattle |
Moléculas de ligaçao especificas para cd37 e especificas para cd20
|
ES2526811T3
(es)
|
2005-08-10 |
2015-01-15 |
Macrogenics, Inc. |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
US7625564B2
(en)
*
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
US9868961B2
(en)
*
|
2006-03-30 |
2018-01-16 |
The Regents Of The University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
US7786270B2
(en)
|
2006-05-26 |
2010-08-31 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
MX2008015524A
(es)
|
2006-06-12 |
2009-01-13 |
Trubion Pharmaceuticals Inc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
JP5764290B2
(ja)
|
2006-06-26 |
2015-08-19 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体およびその使用法
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
ES2457072T3
(es)
|
2006-08-14 |
2014-04-24 |
Xencor, Inc. |
Anticuerpos optimizados que seleccionan como diana CD19
|
CA2660795C
(en)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
JP5926475B2
(ja)
*
|
2006-09-21 |
2016-05-25 |
ユニバーシティー オブ ロチェスター |
筋緊張性ジストロフィーのためのタンパク質置換治療に関する組成物および方法
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
WO2008151088A2
(en)
|
2007-06-01 |
2008-12-11 |
University Of Maryland, Baltimore |
Immunoglobulin constant region fc receptor binding agents
|
BRPI0814465B1
(pt)
|
2007-07-26 |
2021-11-23 |
Novagen Holding Corporation |
Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
|
WO2009058564A2
(en)
*
|
2007-11-01 |
2009-05-07 |
Maxygen, Inc. |
Immunosuppressive polypeptides and nucleic acids
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
EP3575317A1
(de)
|
2007-12-26 |
2019-12-04 |
Xencor, Inc. |
Fc-varianten mit veränderter bindung zu fcrn
|
JP5541845B2
(ja)
*
|
2008-03-28 |
2014-07-09 |
Jcrファーマ株式会社 |
アトピー性皮膚炎治療剤
|
PL2247304T3
(pl)
|
2008-04-02 |
2017-01-31 |
Macrogenics, Inc. |
Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
|
ES2589912T3
(es)
|
2008-04-02 |
2016-11-17 |
Macrogenics, Inc. |
Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
|
WO2009126944A1
(en)
|
2008-04-11 |
2009-10-15 |
Trubion Pharmaceuticals, Inc. |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US7915222B2
(en)
*
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
JP5563572B2
(ja)
|
2008-07-23 |
2014-07-30 |
ハンミ サイエンス カンパニー リミテッド |
三末端官能基を有する非ペプチド性重合体を用いた生理活性ポリペプチド薬物結合体
|
CN102203125A
(zh)
*
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
NZ591130A
(en)
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
ES2657220T3
(es)
|
2008-10-02 |
2018-03-02 |
Aptevo Research And Development Llc |
Proteínas de unión multi-diana antagonistas de CD86
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
MX2011010159A
(es)
|
2009-04-02 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
CN102361883A
(zh)
|
2009-04-07 |
2012-02-22 |
罗氏格黎卡特股份公司 |
双特异性抗-ErbB-1/抗-c-Met抗体
|
EP2417159A1
(de)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Bispezifische anti-erbb-3/anti-c-met-antikörper
|
CA2759333A1
(en)
*
|
2009-04-22 |
2010-10-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
EP2435473B1
(de)
|
2009-05-27 |
2013-10-02 |
F.Hoffmann-La Roche Ag |
Tri- oder tetraspezifische antikörper
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
RU2012109451A
(ru)
|
2009-08-14 |
2013-09-27 |
Роше Гликарт Аг |
Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
SI2486141T1
(en)
|
2009-10-07 |
2018-06-29 |
Macrogenics, Inc. |
FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE
|
SI2516469T1
(sl)
|
2009-12-22 |
2016-05-31 |
Roche Glycart Ag |
Protitelesa proti her3 in uporabe le-teh
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
NZ701539A
(en)
|
2010-03-04 |
2015-04-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
WO2011109280A1
(en)
|
2010-03-05 |
2011-09-09 |
Lerner Research Institute |
Methods and compositions to treat immune-mediated disorders
|
CN102822198B
(zh)
|
2010-03-12 |
2016-08-31 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
CA2795544A1
(en)
|
2010-04-27 |
2011-11-03 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
TR201906652T4
(tr)
|
2010-07-28 |
2019-05-21 |
Gliknik Inc |
Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri.
|
MX339622B
(es)
|
2010-08-02 |
2016-06-02 |
Macrogenics Inc |
Diacuerpos covalentes y sus usos.
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
BR112013014522A2
(pt)
|
2010-12-16 |
2017-09-26 |
Roche Glycart Ag |
anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
AR085403A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
WO2012142434A2
(en)
*
|
2011-04-15 |
2012-10-18 |
THE UNITED STATES OF AMERICA, as represented by the secretary, Depart.of Healtth and Human Services |
Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
|
WO2012145523A2
(en)
|
2011-04-20 |
2012-10-26 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
|
JP6145088B2
(ja)
|
2011-05-21 |
2017-06-07 |
マクロジェニクス,インコーポレーテッド |
脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
|
AU2012260601B2
(en)
|
2011-05-25 |
2018-02-01 |
Innate Pharma, S.A. |
Anti-KIR antibodies for the treatment of inflammatory disorders
|
RU2014114119A
(ru)
|
2011-09-23 |
2015-10-27 |
Рош Гликарт Аг |
Биспецифические анти-egfr/анти igf-1r-антитела
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
JP2015506372A
(ja)
*
|
2012-01-27 |
2015-03-02 |
グリックニック インコーポレイテッド |
IgG2ヒンジドメインを含む融合タンパク質
|
RU2644341C2
(ru)
|
2012-02-10 |
2018-02-08 |
Дженентек, Инк. |
Одноцепочечные антитела и другие гетеромультимеры
|
WO2013148049A1
(en)
*
|
2012-03-29 |
2013-10-03 |
The General Hospital Corporation |
Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
|
JP6228971B2
(ja)
|
2012-05-11 |
2017-11-08 |
メディミューン,エルエルシー |
Ctla−4バリアント
|
CN104379604A
(zh)
|
2012-05-24 |
2015-02-25 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体
|
US8735359B2
(en)
*
|
2012-05-24 |
2014-05-27 |
Orban Biotech Llc |
Combinations of modalities for the treatment of diabetes
|
WO2013192504A1
(en)
|
2012-06-22 |
2013-12-27 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
EP2867253B1
(de)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Verfahren zur auswahl und herstellung massgeschneiderter, hochselektiver und multispezifischer targeting-einheiten mit mindestens zwei verschiedenen bindungseinheiten sowie verwendungen davon
|
AU2013284460A1
(en)
|
2012-06-27 |
2015-01-29 |
Dmnomore |
CTLA4 fusion proteins for the treatment of diabetes
|
CA2871882A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
HRP20211641T1
(hr)
|
2012-07-13 |
2022-02-04 |
Roche Glycart Ag |
Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
|
ES2771324T3
(es)
|
2012-08-03 |
2020-07-06 |
Dana Farber Cancer Inst Inc |
Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
|
MX2015002269A
(es)
|
2012-08-20 |
2015-07-06 |
Gliknik Inc |
Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente.
|
WO2014036468A2
(en)
|
2012-08-31 |
2014-03-06 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Aav mediated aquaporin gene transer to treat sjogren's syndrome
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
LT2968520T
(lt)
|
2013-03-14 |
2021-09-27 |
Macrogenics, Inc. |
Bispecifinės molekulės, kurios yra imunoreaktyvios imuninių efektorių ląstelėms, kurios ekspresuoja aktyvuojantį receptorių
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
EP3049442A4
(de)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
HRP20220748T1
(hr)
|
2013-12-24 |
2022-09-02 |
Janssen Pharmaceutica Nv |
Anti-vista antitijela i fragmenti
|
GB2523399B
(en)
|
2014-02-25 |
2019-03-13 |
Orban Tihamer |
A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
PT3148581T
(pt)
|
2014-05-30 |
2020-01-06 |
Henlix Biotech Co Ltd |
Anticorpos antirrecetor do fator de crescimento epidérmico (egfr)
|
CA2951885C
(en)
|
2014-06-11 |
2023-07-04 |
Kathy A. Green |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
CN107108721B
(zh)
|
2014-09-29 |
2021-09-07 |
杜克大学 |
包含hiv-1包膜靶向臂的双特异性分子
|
KR102614189B1
(ko)
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
WO2016094273A1
(en)
|
2014-12-08 |
2016-06-16 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
US9512229B2
(en)
*
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
CA2981312C
(en)
|
2015-03-30 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
JP2018512856A
(ja)
|
2015-04-17 |
2018-05-24 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
調整可能な親和性を有する免疫調節タンパク質
|
EP3108897A1
(de)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antikörper gegen menschliches csf-1r für die induzierung von lymphozytose in lymphomen oder leukämien
|
DK3313882T3
(da)
|
2015-06-24 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Anti-VISTA antistoffer og fragmenter
|
TWI617319B
(zh)
*
|
2015-09-01 |
2018-03-11 |
免疫功坊股份有限公司 |
用以治療病理性血栓的融合蛋白
|
MY197562A
(en)
|
2015-09-21 |
2023-06-23 |
Aptevo Res & Development Llc |
Cd3 binding polypeptides
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
US10899836B2
(en)
|
2016-02-12 |
2021-01-26 |
Janssen Pharmaceutica Nv |
Method of identifying anti-VISTA antibodies
|
CN108699155B
(zh)
|
2016-03-01 |
2023-03-21 |
豪夫迈·罗氏有限公司 |
具有改变的细胞死亡诱导的奥滨尤妥珠单抗变体
|
PE20190353A1
(es)
|
2016-04-15 |
2019-03-07 |
Macrogenics Inc |
Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
|
US20210017281A1
(en)
|
2016-04-15 |
2021-01-21 |
Immunext, Inc. |
Anti-human vista antibodies and use thereof
|
EP3464347B1
(de)
|
2016-06-07 |
2023-05-31 |
Gliknik Inc. |
Cystein-optimierte stradomere
|
EP3257866A1
(de)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modifizierter anti-tnf-antikörper und verwendung davon bei der behandlung von entzündlicher darmerkrankung
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
KR20190095929A
(ko)
|
2016-12-09 |
2019-08-16 |
글리크닉 인코포레이티드 |
다합체화 스트라도머인 gl-2045의 제조 최적화
|
WO2019066603A1
(ko)
|
2017-09-29 |
2019-04-04 |
한미약품 주식회사 |
효력이 향상된 지속성 단백질 결합체
|
MA50360A
(fr)
|
2017-10-10 |
2020-08-19 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
|
CN110305220B
(zh)
*
|
2018-03-27 |
2022-10-11 |
孙嘉琳 |
一种癌靶向增强型抗肿瘤融合蛋白及制备方法及用途
|
CN110305221B
(zh)
*
|
2018-03-27 |
2022-10-11 |
孙嘉琳 |
一种增强型抗肿瘤融合蛋白及制备方法及用途
|
CN112771077A
(zh)
|
2018-08-31 |
2021-05-07 |
瑞泽恩制药公司 |
针对cd3/c20双特异性抗体的减轻细胞因子释放综合征的给药策略
|
EP3962529A4
(de)
|
2019-04-30 |
2023-11-01 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-cx3cr1 und immuncheckpoint-blockierungsreagenzien
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
CN116234568A
(zh)
|
2020-07-07 |
2023-06-06 |
生物技术公司 |
用于hpv阳性癌症的治疗性rna
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
IL309831A
(en)
|
2021-07-13 |
2024-02-01 |
BioNTech SE |
Multispecific binding agents against CD40 and CD137 in combined cancer therapy
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|